Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

BACKGROUND Riluzole is approved for the treatment of amyotrophic lateral sclerosis in most countries. Questions persist about its clinical utility because of high cost and modest efficacy. OBJECTIVES To examine the efficacy of riluzole in prolonging survival and in delaying the use of surrogates (tracheostomy and mechanical ventilation) to sustain survival, and to assess the effect of riluzole upon functional health. SEARCH METHODS We searched the Cochrane Neuromuscular Disease Group Specialized Register (20 April 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (2011, Issue 2), MEDLINE (1966 to April 2011), EMBASE (1980 to May 2011) and made enquiries of authors of trials, Aventis (manufacturer of riluzole) and other experts in the field. SELECTION CRITERIA Types of studies: randomized controlled trials TYPES OF PARTICIPANTS adults with a diagnosis of amyotrophic lateral sclerosis Types of interventions: treatment with riluzole or placebo Types of outcome measures: Primary: pooled hazard ratio of tracheostomy-free survival over all time points with riluzole 100 mg. Secondary: per cent mortality with riluzole 50 mg, 100 mg and 200 mg; neurologic function, muscle strength and adverse events. DATA COLLECTION AND ANALYSIS One author performed data extraction and two other authors checked them. One author checked the data and entered them into the computer. The other authors verified the data entry. We obtained missing data from the trial authors whenever possible. MAIN RESULTS The four trials examining tracheostomy-free survival included a total of 974 riluzole-treated patients and 503 placebo-treated patients. No new randomized controlled trials were found when we updated the searches for this update in 2011. The methodological quality was acceptable and three trials were easily comparable, although one trial (169 participants) included older patients in more advanced stages of amyotrophic lateral sclerosis and one (195 participants) had multiple primary endpoints. Riluzole 100 mg per day provided a benefit for the homogeneous group of patients in the first two trials (hazard ratio (HR) 0.80, 95% confidence internal (CI) 0.64 to 0.99, P= 0.042) and there was no evidence of heterogeneity (P = 0.33). When the third trial (which included older and more seriously affected patients) was added, there was evidence of heterogeneity (P < 0.0001) and the overall treatment effect was reduced but still significant (HR 0.84, 95% CI 0.698 to 0.997, P= 0.046). This represented a 9% gain in the probability of surviving one year (49% in the placebo and 58% in the riluzole group), and increased median survival from 11.8 to 14.8 months. There was a small beneficial effect on both bulbar and limb function, but not on muscle strength. A three-fold increase in serum alanine transferase was more frequent in riluzole-treated patients than controls (mean difference 2.62, 95% CI 1.59 to 4.31). AUTHORS' CONCLUSIONS Riluzole 100 mg daily is reasonably safe and probably prolongs median survival by about two to three months in patients with amyotrophic lateral sclerosis.

[1]  D. Altman,et al.  Assessing Risk of Bias in Included Studies , 2008 .

[2]  P. Barton,et al.  The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review. , 2001, Health technology assessment.

[3]  P. Sojka,et al.  Effects of riluzole on symptom progression in amyotrophic lateral sclerosis , 1997, The Lancet.

[4]  J. Hugon ALS therapy , 1996, Neurology.

[5]  R. Sufit,et al.  Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review) , 1999, Neurology.

[6]  V. Meininger,et al.  A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis , 2002, Journal of Neurology.

[7]  B. Brooks,et al.  El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[8]  A. Wuerz,et al.  High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study , 2005, Journal of Neural Transmission.

[9]  P. Shaw,et al.  Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial , 2006, The Lancet Neurology.

[10]  L. Rowland Riluzole for the treatment of amyotrophic lateral sclerosis--too soon to tell? , 1994, The New England journal of medicine.

[11]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[12]  J. Cedarbaum,et al.  Prognostic indicators of survival in ALS , 1998, Neurology.

[13]  P. Leigh,et al.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.

[14]  V. Meininger,et al.  A double‐blind, placebo‐controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis , 1989, Neurology.

[15]  J. Petajan,et al.  Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS , 1996, Neurology.

[16]  L. Borderías-Clau,et al.  Alta sospecha de toxicidad pulmonar por riluzol , 2006 .

[17]  J. Hugon Riluzole and ALS therapy. , 1996, Wiener Medizinische Wochenschrift.

[18]  V. Meininger,et al.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.

[19]  E. Sorenson An acute, life-threatening, hypersensitivity reaction to riluzole , 2006, Neurology.

[20]  J. Rothstein,et al.  Therapeutic horizons for amyotrophic lateral sclerosis , 1996, Current Opinion in Neurobiology.

[21]  P. Barton,et al.  Riluzole for motor neurone disease , 2001, BMJ : British Medical Journal.

[22]  G. Logroscino,et al.  Efficacy of riluzole: Who are the patients enrolled in the studies? , 2007, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[23]  V. Meininger,et al.  Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[24]  P. Giacomini,et al.  The effect of riluzole in amyotrophic lateral sclerosis: a study with cortical stimulation , 1999, Journal of the Neurological Sciences.

[25]  D. Arnold,et al.  Recovery of N‐acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy , 1998, Neuroreport.

[26]  E. Beghi,et al.  Riluzole and amyotrophic lateral sclerosis survival: a population‐based study in southern Italy , 2007, European journal of neurology.

[27]  Riluzole-induced neutropenia , 2004, Neurology.

[28]  R. Sufit,et al.  Clinical trials of riluzole in patients with ALS , 1996, Neurology.

[29]  L. Borderías-Clau,et al.  [Strong suspicion of lung toxicity due to riluzole]. , 2006, Archivos de bronconeumologia.

[30]  R. Andrade,et al.  Riluzole-induced acute pancreatitis , 2001, American Journal of Gastroenterology.

[31]  H. Mitsumoto,et al.  Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review) , 2009, Neurology.

[32]  V. Meininger,et al.  The Riluzole Early Access Programme: descriptive analysis of 844 patients in France , 1997, Journal of Neurology.

[33]  V. Meininger,et al.  An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. , 1998, Archives of neurology.

[34]  D. Mitchell,et al.  Audit of outcomes in motor neuron disease (MND) patients treated with riluzole , 2006, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[35]  W. Camu,et al.  Acute hepatitis after riluzole administration. , 1999, Journal of hepatology.